(Q53770761)

19 May 2018

title

Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa. (English)

1 reference

19 May 2018

recessive dystrophic epidermolysis bullosa

main subject

0 references

author

Alexander Nyström

3

1 reference

19 May 2018

Josef Penninger

6

1 reference

19 May 2018

Leena Bruckner-Tuderman

4

object named as

Leena Bruckner-Tuderman

1 reference

19 May 2018

Arabella Meixner

5

object named as

Arabella Meixner

1 reference

19 May 2018

author name string

Daniel Wenzel

1

1 reference

19 May 2018

Jonathan Bayerl

2

1 reference

19 May 2018

language of work or name

English

0 references

publication date

1 November 2014

1 reference

19 May 2018

Science Translational Medicine

published in

1 reference

19 May 2018

volume

6

1 reference

19 May 2018

issue

264

1 reference

19 May 2018

page(s)

264ra165

1 reference

19 May 2018

Epidermolysis bullosa - a group of skin diseases with different causes but commonalities in gene expression

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Progress in Epidermolysis bullosa research: summary of DEBRA International Research Conference 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

The role of systematic reviews and meta-analysis in dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Germline Mutation in EXPH5 Implicates the Rab27B Effector Protein Slac2-b in Inherited Skin Fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

A consensus approach to wound care in epidermolysis bullosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Progress in epidermolysis bullosa research: toward treatment and cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Intravenously injected human fibroblasts home to skin wounds, deliver type VII collagen, and promote wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Bone marrow stem cell therapy for recessive dystrophic epidermolysis bullosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Reprogrammed cells for disease modeling and regenerative medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

iPS cells: a game changer for future medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Revertant mosaicism in skin: natural gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Successful therapeutic transplantation of revertant skin in epidermolysis bullosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Gene therapy for skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

A hypomorphic mouse model of dystrophic epidermolysis bullosa reveals mechanisms of disease and response to fibroblast therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Collagen VII plays a dual role in wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Transforming growth factor-beta stimulates collagen VII expression by cutaneous cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Differentiation of mouse induced pluripotent stem cells into a multipotent keratinocyte lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Mechanisms of fibroblast cell therapy for dystrophic epidermolysis bullosa: high stability of collagen VII favors long-term skin integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Distinct fibroblast lineages determine dermal architecture in skin development and repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Type VII collagen is required for Ras-driven human epidermal tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

DeltaNp63 is essential for epidermal commitment of embryonic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Keratin intracellular concentration revisited: implications for keratin function in surface epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

Matrix metalloproteinase-7 activates heparin-binding epidermal growth factor-like growth factor in cutaneous squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

High-efficiency FLP and PhiC31 site-specific recombination in mammalian cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3010083

10.1126/SCITRANSLMED.3010083

21 January 2018

Identifiers

DOI

1 reference

19 May 2018

1 reference

19 May 2018